Free tool
FAERS Monitor: Wynzora
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213422 or its brand name (Wynzora, Betamethasone Dipropionate, Calcipotriene). Reports on generic versions are filed under their own applications.
Reports
428
Serious
296
69% of reports
Hospitalization
107
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- psoriasis123
- drug ineffective70
- pruritus53
- fatigue40
- pain37
- arthralgia33
- diarrhoea32
- rash31
- nasopharyngitis30
- inappropriate schedule of product administration29
- psoriatic arthropathy29
- cellulitis26
- headache26
- pneumonia26
- erythema25
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 11 |
| 2012 | 16 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 39 |
| 2017 | 38 |
| 2018 | 34 |
| 2019 | 50 |
| 2020 | 49 |
| 2021 | 38 |
| 2022 | 47 |
| 2023 | 46 |
| 2024 | 28 |
| 2025 | 14 |
| 2026 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,731 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriasisSignal | 123 | 46.3 | 39.9 | 5,438 |
| psoriatic arthropathySignal | 29 | 35.1 | 24.7 | 929 |
| cellulitisSignal | 26 | 25.4 | 17.5 | 586 |
| nasopharyngitisSignal | 30 | 8.0 | 5.7 | 178 |
| inappropriate schedule of product administrationSignal | 29 | 7.9 | 5.6 | 170 |
| pruritusSignal | 53 | 6.8 | 5.3 | 260 |
| erythemaSignal | 25 | 6.0 | 4.1 | 100 |
| pneumoniaSignal | 26 | 3.9 | 2.7 | 55 |
| arthralgiaSignal | 33 | 3.9 | 2.8 | 70 |
| rashSignal | 31 | 3.5 | 2.5 | 54 |
| painSignal | 37 | 3.0 | 2.2 | 47 |
| drug ineffectiveSignal | 70 | 2.6 | 2.1 | 72 |
| fatigueSignal | 40 | 2.5 | 1.9 | 37 |
| diarrhoeaSignal | 32 | 2.4 | 1.7 | 26 |
| headacheSignal | 26 | 2.0 | 1.4 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.